The New England Journal of Medicine December 15, 2011

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

AIM-HIGH Investigators (William E. Boden, Jeffrey L. Probstfield, Todd Anderson, Bernard R. Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub)

Source: View publication →

Bottom Line

The AIM-HIGH trial demonstrated that adding extended-release niacin to intensive statin therapy in patients with established cardiovascular disease, well-controlled LDL cholesterol, and atherogenic dyslipidemia significantly improved HDL and triglyceride levels but did not reduce the risk of cardiovascular events.

Key Findings

1. Extended-release niacin significantly improved lipid profiles at 2 years compared to baseline, increasing median HDL from 35 mg/dL to 42 mg/dL, lowering triglycerides from 164 mg/dL to 122 mg/dL, and lowering LDL from 74 mg/dL to 62 mg/dL.

2. Despite these improvements, there was no significant difference in the primary composite endpoint, which occurred in 16.4% of the niacin group and 16.2% of the placebo group (hazard ratio, 1.02; 95% CI, 0.87 to 1.21; P=0.79).

3. There was an unexpected excess of ischemic strokes in the niacin group (1.6%, 27 events) compared to the placebo group (0.9%, 15 events), which alongside a lack of efficacy contributed to the early termination of the trial for futility.

Study Design

Design

RCT

Double-Blind

Sample

3,414

Patients

Duration

3.0 yr

Median

Setting

US and Canada

Population Patients with established atherosclerotic cardiovascular disease, atherogenic dyslipidemia (low HDL, elevated triglycerides), and well-controlled LDL cholesterol on statin therapy.

Intervention Extended-release niacin (1500 to 2000 mg/day) added to simvastatin therapy (with ezetimibe if needed to maintain LDL < 80 mg/dL).

Comparator Matching placebo (containing 50 mg immediate-release niacin to mimic flushing) added to simvastatin therapy.

Outcome First occurrence of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization.

Study Limitations

• The trial was terminated early for futility after a mean follow-up of 3.0 years, potentially limiting the statistical power to detect long-term benefits.

• Patients in both treatment arms received intensive statin and ezetimibe therapy maintaining extremely low baseline LDL cholesterol levels (mean ~71 mg/dL), which minimized baseline cardiovascular risk and left less room for additional therapies to show an incremental benefit.

• To maintain blinding, the placebo contained a small dose of immediate-release niacin (50 mg per tablet), which modestly raised HDL in the control group and narrowed the treatment difference between the two arms.

• High discontinuation rates primarily driven by niacin-associated adverse effects (like flushing) could have diluted the power of the intention-to-treat analysis.

Clinical Significance

AIM-HIGH provided definitive evidence that pharmacologically raising HDL cholesterol and lowering triglycerides with extended-release niacin confers no incremental cardiovascular benefit in patients whose LDL is already well-controlled on statins. This landmark trial effectively ended the routine use of niacin for secondary cardiovascular prevention and seriously undermined the HDL hypothesis.

Historical Context

Prior to AIM-HIGH, epidemiological data consistently showed that low HDL cholesterol was a powerful independent predictor of cardiovascular risk, and older secondary prevention trials (like the Coronary Drug Project) suggested niacin reduced events. AIM-HIGH was specifically designed to test the 'HDL hypothesis' in the modern statin era. Its decisively negative results, later corroborated by the HPS2-THRIVE trial, catalyzed a major paradigm shift away from HDL-raising interventions.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the proposed mechanism by which niacin raises HDL cholesterol, and based on the AIM-HIGH trial, does pharmacologically raising HDL in a patient already on a statin provide additional cardiovascular benefit?

Key Response

Niacin decreases hepatic VLDL secretion and inhibits adipose tissue lipolysis, lowering LDL and triglycerides while raising HDL by decreasing the clearance of apoA-I. However, AIM-HIGH showed that despite successfully raising HDL and lowering triglycerides, adding niacin to intensive statin therapy did not reduce cardiovascular events, fundamentally challenging the clinical utility of the HDL hypothesis.

Resident

A patient with established CAD is on high-intensity statin therapy with an LDL of 65 mg/dL but has an HDL of 32 mg/dL. They ask if they should start taking over-the-counter niacin supplements to protect their heart. How should you counsel them regarding efficacy and potential adverse effects?

Key Response

You should advise against adding niacin. The AIM-HIGH trial demonstrated no cardiovascular benefit when adding niacin to statin therapy in patients with controlled LDL. Furthermore, niacin can cause bothersome flushing, hyperglycemia, hyperuricemia (gout), and hepatotoxicity, making the risk-benefit ratio unfavorable for cardiovascular event reduction.

Fellow

How does the early termination of the AIM-HIGH trial for futility, combined with the slight numerical increase in ischemic strokes observed in the niacin arm, reshape our understanding of managing residual cardiovascular risk in patients with atherogenic dyslipidemia?

Key Response

The trial highlights that residual risk in statin-treated patients is not reliably modifiable simply by targeting HDL-C concentration. The unexplained trend toward increased ischemic stroke suggests potential off-target toxicities. It shifts the subspecialty focus toward targeting apoB-containing lipoproteins, Lp(a), or inflammatory pathways rather than HDL-C mass.

Attending

For decades, raising HDL was a major therapeutic target. How do we use the results of AIM-HIGH to teach trainees about the critical difference between epidemiological markers of risk and viable pharmacological targets?

Key Response

AIM-HIGH perfectly illustrates the trap of epidemiological confounding. While low HDL is a robust biomarker for cardiovascular risk, it is likely a marker of poor metabolic health (e.g., insulin resistance, high remnant cholesterol) rather than a causal, modifiable factor in isolation. This teaches trainees the necessity of randomized controlled trials to prove that modulating a biomarker actually translates to clinical outcomes.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The AIM-HIGH trial utilized an active placebo containing 50 mg of immediate-release niacin to mimic the flushing side effect of the intervention arm. What are the methodological strengths and limitations of this active-placebo approach in a cardiovascular outcome trial?

Key Response

The active placebo maintains blinding, which is critical since niacin-induced flushing is notoriously difficult to mask. However, a limitation is that even 50 mg of niacin might have minor biological effects. Coupled with the fact that both groups received intensive background statin therapy to match LDL levels, the delta in lipid profiles between groups was minimized, potentially shrinking the effect size and reducing statistical power to detect an outcome difference.

Journal Editor

The trial was halted prematurely for futility after an average follow-up of 3 years. As a statistical reviewer, what concerns would you raise regarding the decision to stop early, particularly concerning the power to detect long-term macrovascular benefits?

Key Response

Stopping for futility prevents exposure to ineffective drugs, but it can mask delayed benefits. Niacin's theoretical mechanism of plaque stabilization or regression might take longer than 3 years to manifest clinically, especially in a population already heavily treated with statins. A rigorous reviewer would scrutinize whether the futility boundary was too aggressive, potentially missing a delayed divergence in Kaplan-Meier event curves.

Guideline Committee

Based on the AIM-HIGH findings, how should major lipid guidelines classify the use of niacin for cardiovascular risk reduction in patients with ASCVD who are already on maximally tolerated statin therapy?

Key Response

Following AIM-HIGH and the subsequent HPS2-THRIVE trial, the AHA/ACC guidelines classify niacin as a Class III recommendation (No Benefit/Harm) for addition to statins. AIM-HIGH provides Level of Evidence A that despite favorable surrogate lipid profile changes, niacin does not reduce ASCVD events and introduces potential harms, formally removing it from the standard secondary prevention algorithm.

Clinical Landscape

Noteworthy Related Trials

2010

ACCORD Lipid

n = 5,518 · NEJM

Tested

Fenofibrate added to simvastatin

Population

Patients with type 2 diabetes at high cardiovascular risk

Comparator

Placebo

Endpoint

First occurrence of nonfatal MI, nonfatal stroke, or cardiovascular death

Key result: Adding fenofibrate to statin therapy did not reduce the rate of fatal cardiovascular events, nonfatal MI, or nonfatal stroke overall.

2014

HPS2-THRIVE

n = 25,673 · NEJM

Tested

Extended-release niacin-laropiprant

Population

Patients with prior vascular disease on statin therapy

Comparator

Placebo

Endpoint

Major vascular events

Key result: Adding niacin-laropiprant to statin therapy did not significantly reduce the risk of major vascular events but increased the risk of serious adverse events.

2018

REDUCE-IT

n = 8,179 · NEJM

Tested

Icosapent ethyl 4g daily

Population

Statin-treated patients with cardiovascular disease or diabetes and elevated triglycerides

Comparator

Placebo

Endpoint

Composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina

Key result: Icosapent ethyl significantly reduced the risk of ischemic events, including cardiovascular death, compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis